<?xml version="1.0" encoding="utf-8"?>  
		   <iati-activities version="2.03" generated-datetime="2026-10-15T19:16:29">
		   <iati-activity last-updated-datetime="2026-10-15T19:16:29"
		   xml:lang="EN" default-currency="USD" hierarchy="01">
		   <iati-identifier>XI-IATI-WBTF-TF073106</iati-identifier>
		   <reporting-org ref="XI-IATI-WBTF" type="40">  
		   		   <narrative>World Bank Trust Funds</narrative>
		   </reporting-org>
		   <title>
		   <narrative>HIV Vaccine Research and Development Trust Fund	   </narrative>
		   </title>
		   <description type="1">
		   <narrative>&quot;The Objective of the trust fund is to develop and characterize
 viable HIV vaccine candidate(s) and other potential viral vectors as basic research for new technologies against infectious diseases of poverty.&quot; </narrative>
		   </description><participating-org ref="TF513001" type="10" role="1" >
       <narrative>Japan - Ministry of Finance </narrative>
       </participating-org><participating-org ref="XI-IATI-WBTF" type="40" role="4" >
       <narrative>World Bank Trust Funds </narrative>
       </participating-org> <activity-status code="3"></activity-status><activity-date type="1"  iso-date= "2018-07-16"></activity-date><activity-date type="2"  iso-date= "2018-07-16"></activity-date><activity-date type="3"  iso-date= "2021-12-31"></activity-date><activity-date type="4"  iso-date= "2022-02-16"></activity-date> <contact-info type="3">
       <organisation>
       <narrative></narrative>
       </organisation>
       <department>
       <narrative>HIS-Health, Nutr &amp; Population - GP</narrative>
       </department>
       <person-name>
       <narrative></narrative>
       </person-name>
       <job-title>
       <narrative></narrative>
       </job-title>
       <telephone>1202-458-7916</telephone>
       <email></email>
       <mailing-address>
       <narrative>1818 H St, NW, Washington DC - 22036</narrative>
       </mailing-address>
       </contact-info><activity-scope code="1"></activity-scope> <recipient-region code="998">   <narrative>Bilateral unspecified</narrative>
       </recipient-region> <sector code="12250" 
	    vocabulary="1" percentage="100.00">
       <narrative>+![cdata[Infectious disease control]]+</narrative>
       </sector><collaboration-type code="2"></collaboration-type>
       <default-aid-type code="B03"></default-aid-type>
       <default-tied-status code="5"></default-tied-status><budget type="1">
       <period-start iso-date="2018-07-16"></period-start> 
       <period-end iso-date="2021-12-31"> </period-end>
       <value currency="USD" value-date="2026-03-31">6340000.00 </value>
       </budget><transaction>
	  <transaction-type code="1"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">4340000.00  </value>
		   <description>
       <narrative>Incoming Funds (Cumulative Paid-In Contribution )-as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="TF513001">
       <narrative>Japan - Ministry of Finance</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="1"></transaction-type>
       <transaction-date iso-date="2021-05-31"></transaction-date>
       <value currency="USD" value-date="2026-03-31">2000000.00  </value>
		   <description>
       <narrative>Incoming Funds (Paid-In Contribution ) -  for May , 2021</narrative> 
       </description> 
	    <provider-org provider-activity-id="TF513001">
       <narrative>Japan - Ministry of Finance</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">6340000.00  </value>
		   <description>
       <narrative>Incoming Commitment(Cumulative Signed Contribution)-as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="TF513001">
       <narrative>Japan - Ministry of Finance</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="2"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">300000.00  </value>
		   <description>
       <narrative>Allocation to Bank executed activities - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="2"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">5752381.00  </value>
		   <description>
       <narrative>Outgoing Commitment ( Total Grant Allocated Amount to Project ) - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="2"></transaction-type>
       <transaction-date iso-date="2021-11-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">-629331.71  </value>
		   <description>
       <narrative>Outgoing Commitment ( Grant Allocated Amount Cancellation/Adjustments ) -  for November , 2021</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="2"></transaction-type>
       <transaction-date iso-date="2022-02-28"></transaction-date>
       <value currency="USD" value-date="2026-03-31">-7007.32  </value>
		   <description>
       <narrative>Allocation to Bank executed activities ( Cancellation/Adjustments ) -  for February , 2022</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><related-activity ref="XI-IATI-WBTF-P167064"  type="2"></related-activity>
   </iati-activity>	<iati-activity last-updated-datetime="2026-10-15T19:16:31"
	   xml:lang="EN" default-currency="USD" hierarchy="02">
       <iati-identifier>XI-IATI-WBTF-P167064</iati-identifier>
       <reporting-org ref="XI-IATI-WBTF"  type="40">
       <narrative>World Bank Trust Funds</narrative>
       </reporting-org>
       <title>
       <narrative>HIV Vaccine Research and Development</narrative>
       </title>
       <description type="1">
       <narrative>To develop and characterize viable HIV vaccine candidate(s) and other potential viral vectors as basic research for new technologies against infectious diseases of poverty.  </narrative>
	   </description><participating-org ref="TF073106" type="40" role="4" >
       <narrative>HIV Vaccine Research and Development Trust Fund </narrative>
       </participating-org><participating-org ref="TF513001" type="10" role="1" >
       <narrative>Japan - Ministry of Finance </narrative>
       </participating-org> <activity-status code="3"></activity-status><activity-date type="1"  iso-date= "2018-09-05"></activity-date><activity-date type="2"  iso-date= "2018-09-05"></activity-date><activity-date type="3"  iso-date= "2021-12-31"></activity-date><activity-date type="4"  iso-date= "2021-11-30"></activity-date> <contact-info type="2">
       <organisation>
       <narrative></narrative>
       </organisation>
       <department>
       <narrative></narrative>
       </department>
       <person-name>
       <narrative>Mr Robert Oelrichs</narrative>
       </person-name>
       <job-title>
       <narrative>Short Term Consultant</narrative>
       </job-title>
       <telephone>1202-458-7916</telephone>
       <email></email>
       <mailing-address>
       <narrative>1818 H St, NW, Washington DC - 22036</narrative>
       </mailing-address>
       </contact-info><activity-scope code="1"></activity-scope> <recipient-region code="998">   <narrative>Bilateral unspecified</narrative>
       </recipient-region> <sector code="12250"  vocabulary="1" percentage="100.00">
       <narrative>+![cdata[Infectious disease control]]+</narrative>
       </sector><collaboration-type code="2"></collaboration-type>
       <default-aid-type code="C01"></default-aid-type>
       <default-tied-status code="5"></default-tied-status><budget type="1">
       <period-start iso-date="2018-09-05"></period-start> 
       <period-end iso-date="2021-12-31"> </period-end>
       <value currency="USD" value-date="2026-03-31">5416041.97 </value>
       </budget><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">300000.00  </value>
		   <description>
       <narrative>Allocation to Bank executed activities - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="P167064">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">5752381.00  </value>
		   <description>
       <narrative>Incoming Commitment (Total Grant Allocated Amount) - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="P167064">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2021-11-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">-629331.71  </value>
		   <description>
       <narrative>Incoming Commitment ( Grant Allocated Amount cancellation/Adjustments ) -  for November , 2021</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="P167064">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2022-02-28"></transaction-date>
       <value currency="USD" value-date="2026-03-31">-7007.32  </value>
		   <description>
       <narrative>Allocation to Bank executed activities ( Cancellation/Adjustments ) -  for February , 2022</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF073106">
       <narrative>HIV Vaccine Research and Development Trust Fund</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="P167064">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="3"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">2531110.80  </value>
		   <description>
       <narrative>Disbursement(Total Recipient-Executed Trust Funds Disbursements ) - as of June 30th, 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="3"></transaction-type>
       <transaction-date iso-date="2020-09-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">408836.94  </value>
		   <description>
       <narrative>Disbursement(Recipient-Executed Trust Funds Disbursements ) -  for September , 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="3"></transaction-type>
       <transaction-date iso-date="2021-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">1409859.49  </value>
		   <description>
       <narrative>Disbursement(Recipient-Executed Trust Funds Disbursements ) -  for June , 2021</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="3"></transaction-type>
       <transaction-date iso-date="2021-10-31"></transaction-date>
       <value currency="USD" value-date="2026-03-31">773242.06  </value>
		   <description>
       <narrative>Disbursement(Recipient-Executed Trust Funds Disbursements ) -  for October , 2021</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">120580.09  </value>
		   <description>
       <narrative>Cumulative Expenditures to Bank executed activities - as of June 30th, 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2020-07-31"></transaction-date>
       <value currency="USD" value-date="2026-03-31">3069.00  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of July , 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2020-08-31"></transaction-date>
       <value currency="USD" value-date="2026-03-31">11438.93  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of August , 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2020-09-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">15650.08  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of September , 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2020-10-31"></transaction-date>
       <value currency="USD" value-date="2026-03-31">11774.91  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of October , 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2020-11-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">15091.69  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of November , 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2020-12-31"></transaction-date>
       <value currency="USD" value-date="2026-03-31">7507.04  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of December , 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2021-01-31"></transaction-date>
       <value currency="USD" value-date="2026-03-31">10872.60  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of January , 2021</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2021-02-28"></transaction-date>
       <value currency="USD" value-date="2026-03-31">12815.38  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of February , 2021</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2021-03-31"></transaction-date>
       <value currency="USD" value-date="2026-03-31">19269.25  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of March , 2021</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2021-04-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">11495.11  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of April , 2021</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2021-05-31"></transaction-date>
       <value currency="USD" value-date="2026-03-31">41890.17  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of May , 2021</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2021-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">11538.43  </value>
		   <description>
       <narrative>Expenditures to Bank executed activities -  for the month of June , 2021</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P167064">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><related-activity ref="XI-IATI-WBTF-TF073106" type="1"></related-activity><result type="2" aggregation-status="0">
<title><narrative>
 PDO Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.1 VSV-∆G (HIV.Env) vector fully characterized including in immunological, genetic and cellular propagation aspects
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" />  <period-end iso-date="2021-05-31" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="2" aggregation-status="0">
<title><narrative>
 PDO Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.2.Two further novel vectors (VSV(NJ) and a novel VSV-like vector) constructed and characterized
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" />  <period-end iso-date="2020-06-24" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="2" aggregation-status="0">
<title><narrative>
 PDO Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.3.GMP compliant cell line for use in manufacturing of VSV-based HIV vaccine vectors produced
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" />  <period-end iso-date="2020-12-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="2" aggregation-status="0">
<title><narrative>
 PDO Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
2.Joint learning events and meeting outputs developed with global partners in vaccine R&amp;D for potential epidemic diseases and diseases of poverty
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" />  <period-end iso-date="2021-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.1.a  Primary sample analysis, antibody titers (Elisa) and T-cell from animals immunized with the VSV∆G-Env vector completed.
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.2.a  Technical feasibility of two approaches to producing a VSV G pseudotyping cell including: G expression following extended cell passage and ability to propagate VSV∆G-Env vector determined.
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.1.c  Analysis of blood transcriptomic profiles at select time points after vaccination completed and how vaccination affects modular gene sets such as those connected to B- and T-cell responses etc.
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.2.c A GMP compliant cell line of for use in GMP manufacturing of VSV based HIV vaccine vectors produced, if the pseudotyping cellline has been demonstrated to be feasible.
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.3.c In addition to VSV(NJ), a second new vector developed and characterized based on an immunologically distant VSV-like virus tobe determined after database sequence comparison.
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
2.c Field visit(s) by potential global partners organized.
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.1.d  Analysis of samples collected from animals from study IAVI#1601 and 3-4 small pilot studies conducted to specifically quantify and compare cytokines and chemokines induced by vaccination
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.3.d If appropriate based on result from 3.a and 3.c,  (up to) two new vector backbone (HIV.Env) candidates selected for use in vaccine development used to product material comparable to the research
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.3.a  A VSV(NJ)∆G-Env vector shown to have replicative capacity equivalent to the original VSV∆G-Env counterpart based on VSV(IND)constructed.
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
2.a Joint meetings to reach out to potential global partners organized three times.
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.1.b  Advanced characterization of Env-specific serum antibodies induced by vaccination completed incl. epitope specificity determination by binding and competition assays &amp; evaluation of effects
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.2.b Technical feasibility of ( a)DNA expression construct encoding alternative G glycoprotein less cytotoxic (b)DNA expression construct encoding alternative viral glycoprotein &amp; supports VSV pseudo
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
1.3.b  A second vector platform for further evaluation &amp; development from among, but not limited to VSVlike viruses (Cocal, Carajas, Maraba) or other more immunologically distant relatives identified
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
2.b Communication material for global partners developed.
</narrative></title> 
<baseline year="2018" iso-date="2018-10-01" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2018-10-01" /> <period-end iso-date="1900-01-01"/>
<target value="">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result></iati-activity></iati-activities>